Navigation Links
Cambrex Reports Fourth Quarter and Full-Year 2007 Results
Date:2/14/2008

EAST RUTHERFORD, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports fourth quarter and full-year 2007 results for the period ended December 31, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

Summary

-- Fourth quarter 2007 sales increased 5.7% (-0.2% excluding foreign

currency) compared to fourth quarter 2006. Full year sales were up

6.7% (2.0% excluding foreign currency) compared to 2006.

-- Gross Margin for the quarter increased to 34.9% of sales compared to

33.5% last year. Full year Gross Margin increased to 36.1% compared

to 35.4% in 2006.

-- Operating Profit before corporate, strategic alternatives and

restructuring expenses was $13.3 million or 19.1% of sales in the

fourth quarter of 2007 versus $12.9 million or 19.6% last year. For

the full year, Operating Profit before corporate, strategic

alternatives and restructuring expenses was $51.1 million or 20.2% of

sales, versus $49.2 million or 20.8% for 2006.

-- Debt, net of cash, was $63.3 million at the end of 2007.

-- Sales growth for 2008 is expected to be between 5% and 10% and

Adjusted EBITDA (EBITDA before restructuring and strategic

alternatives costs) is expected to be between $53 and $57 million.

Discontinued Operations and Basis of Reporting

As previously reported, Cambrex sold its Bioproducts and Biopharma businesses (the "Bio Businesses") to Lonza for $463.9 million (after working capital adjustments) in February 2007 and sites in Cork, Ireland and Landen, Bel
'/>"/>

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Cambrex Signs Agreement To Acquire ProSyntest AS
2. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
3. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
4. TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year
5. The Quantum Group Reports 4th Quarter and Year End Results for Fiscal Year 2007
6. Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year-End 2007 Financial Results
7. AtriCure Reports Fourth Quarter and Full Year 2007 Record Financial Results
8. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
9. AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share
10. Allscripts Reports Fourth Quarter 2007 Results
11. IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... NC (PRWEB) July 14, 2014 The ... the University of Pennsylvania to fund a clinical trial ... here to read Surviving Mesothelioma’s newly-posted article on ... plan to use the grant to enroll 102 ... years. Patients will receive a photosensitizing drug prior to ...
(Date:7/14/2014)... SC (PRWEB) July 14, 2014 Many diet ... a study by the School of Public Health at ... vegetable consumption had a near-zero effect on weight loss. Now ... be combine with some form of portion control ... method of monitoring portions and controlling how much is consumed, ...
(Date:7/14/2014)... Washington DC (PRWEB) July 14, 2014 ... MessageSolution, an industry leader and Microsoft gold partner will ... network with Microsoft partners from the world and to ... all Microsoft platforms of Exchange email server, Office 365, ... DC from July 13 to 17, 2014. , “In ...
(Date:7/14/2014)... NATURALLY, DANNY SEO, a new magazine ... with a Fall issue that hits newsstands nationwide on ... the healthy, natural and good for you life with ... beauty, travel, home, and entertaining all through Danny’s unique ... “Instead of gimmicky weight loss tips and fluffy celebrity ...
(Date:7/14/2014)... San Diego, CA (PRWEB) July 14, 2014 ... website daily regarding all the latest information from the ... Injection . , The FDA informed on July 11, ... Injection, USP, 1000 mL, Flexible Container, by Hospira Inc., ... is used for parenteral replacement of extracellular losses of ...
Breaking Medicine News(10 mins):Health News:New Research Could Expand Availability of Light-Based Mesothelioma Therapy, According to Surviving Mesothelioma 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3
... clinical trials, design may also mask risk of HIV drug ... new study questions whether vaginal microbicides being developed to help ... resistance from the virus that causes AIDS. , The ... Proceedings of the National Academy of Sciences , also shows ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
... WASHINGTON, July 10 Two leading U.S. House,Judiciary Committee ... Judiciary Committee and Rep. Lamar Smith, ranking member of ... B. Mukasey to,have the Department of Justice focus its ... seeking to gain control of,U.S. copper miner ASARCO., ...
... 2008 -- Later this month, thousands of scientists and health ... the 50th meeting of the American Association of Physicists in ... July 31, they will present the latest technologies for imaging ... facing the field today. , Whether X-rays for CT ...
... of a noisy Chicago restaurant during the breakfast rush ... many voices was the crucial test of new hearing ... University School of Medicine in St. Louis. The study showed ... the most challenging test for a hearing aid. ,But ...
... Va., July 10 Axiom Resource,Management, Inc., has been ... the field of healthcare information and technology. Healthcare,Informatics magazine ... June, 2008, ranking Axiom at number 76. Axiom moved ... at number 81 on the list., Axiom managing ...
Cached Medicine News:Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 2Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 3Health News:Waves, particles and medicine in Houston 2Health News:New hearing aid technology passes the restaurant noise test 2Health News:New hearing aid technology passes the restaurant noise test 3
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... 4, 2012  Elevation Pharmaceuticals, Inc. announced today the closing ... investor Novo Ventures , to fund development of Elevation,s ... disease (COPD). All previous investors participated in the round, including ... Capital and Mesa Verde Venture Partners . In ...
... 4, 2012 /PRNewswire-iReach/ -- DFH Pharma, ... focused exclusively in the HIV-1 therapeutic space, announced ... medicinal chemistry services to support DFH efforts to ... drugs. Maturation inhibitors are a novel class of ...
Cached Medicine Technology:Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 2Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 3DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
Liquichek Cardiac Markers Control is a multi-analyte liquid control for monitoring cardiac assessment tests. Assayed values are available for major instruments....
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
Medicine Products: